Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: An Italian multi-institutional phase II trial (369 views)
Neuro-Oncology (ISSN: 1522-8517), 2014 May; 16(5): 748-753.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 6.776, 5-year impact factor: 6.604
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-84899437120&partnerID=40&md5=b26db4c05154847234c3c954ac57948b
Keywords: Medulloblastoma, Phase Ii Trial, Temozolomide, Antiemetic Agent, Carboplatin, Cisplatin, Cyclophosphamide, Etoposide, Methotrexate, Nitrosourea Derivative, Vincristine, Adolescent, Adult, Anemia, Article, Bone Marrow Suppression, Cancer Chemotherapy, Cancer Growth, Chemotherapy Induced Nausea And Vomiting, Child, Childhood Cancer, Clinical Article, Craniospinal Irradiation, Drug Dose Reduction, Drug Efficacy, Drug Tolerability, Female, Histology, Human, Italy, Maintenance Chemotherapy, Multicenter Study, Neuroectoderm Tumor, Neutropenia, Overall Survival, Phase 2 Clinical Trial, Progression Free Survival, Thrombocytopenia, Treatment Response, Tumor Recurrence, Tumor Volume, Unspecified Side Effect,
Affiliations:
*** IBB - CNR ***
Pediatrics Unit, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy
Pediatric Oncology, A. Gemelli Hospital, Catholic University, Rome, Italy
Department of Radiodiagnostics, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy
Department of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy
Department of Neurosurgery, Ospedale G. Gaslini, Genova, Italy
Department of Pediatrics, University of Padua, Padua, Italy
Department of Bioimaging and Radiological Sciences, Catholic University, Rome, Italy
References:
Taylor, R.E., Bailey, C.C., Robinson, K., Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The international society of paediatric oncology/united kingdom childrens cancer study group pnet-3 study (2003) J Clin Oncol, 21, pp. 1581-159
Rutkowski, S., Bode, U., Deinlein, F., Treatment of early childhood medulloblastoma by postoperative chemotherapy alone (2005) N Engl J Med, 35, pp. 2978-2986
Evans, A.E., Jenkin, R.D., Sposto, R., The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU vincristine and prednisone (1990) J Neurosurg, 72, pp. 572-582
Bailey, C.C., Gnekow, A., Wellek, S., Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma (1995) Med Pediatr Oncol, 25, pp. 166-178. , International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II
Gatta, G., Capocaccia, R., Coleman, M.P., Childhood cancer survival in Europe and the United States (2002) Cancer, 95 (8), pp. 1767-1772
Dunkel, I.J., Boyett, J.M., Yates, A., High-dose carboplatin thiotepa and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma (1998) J Clin Oncol, 16 (1), pp. 222-228. , Childrens Cancer Group
Massimino, M., Casanova, M., Polastri, D., Relapse in medulloblastoma: What can be done after abandoning high-dose chemotherapy? A mono-institutional experience (2013) Childs Nerv Syst, 29, pp. 1107-1112
Bouffet, E., Doz, F., Demaille, M.C., Improving survival in recurrent medulloblastoma: Earlier detection better treatment or still an impasse? (1998) Br J Cancer, 77, pp. 1321-1326
Gajjar, A., Pizer, B., Role of high-dose chemotherapy for recurrent medulloblastoma and other CNS primitive neuroectodermal tumors (2010) Pediatr Blood Cancer, 54 (4), pp. 649-651
Walter, A.W., Mulhern, R.K., Gajjar, A., Survival and neurodevelopmental outcome of young children with medulloblastoma at St Jude Childrens Research Hospital (1999) J Clin Oncol, 17, pp. 3720-3728
Ostermann, S., Csajka, C., Buclin, T., Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients (2004) Clin Cancer Res, 10, pp. 3728-3736
Panetta, J.C., Kirstein, M.N., Gajjar, A., Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors (2003) Cancer Chemother Pharmacol, 52, pp. 435-441
Patel, M., McCully, C., Godwin, K., Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates (2003) J Neurooncol, 61, pp. 203-207
Ruggiero, A., Cefalo, G., Garré, M.L., Phase II trial of temozolomide in children with recurrent high-grade glioma (2006) J Neurooncol, 77, pp. 89-94
Nicholson, H.S., Krailo, M., Ames, M.M., Phase i study of temozolomide in children and adolescents with recurrent solid tumors: A report from the Childrens Cancer Group (1998) J Clin Oncol, 16, pp. 3037-3043
Estlin, E.J., Lashford, L., Ablett, S., Phase i study of temozolomide in paediatric patients with advanced cancer (1998) Br J Cancer, 78 (5), pp. 652-661. , United Kingdom Childrens Cancer Study Group
Stevens, M.F., Hickman, J.A., Langdon, S.P., Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl- imidazo[5 i-d]-l235-tetrazin-4(3h)-one (ccrg 81045
m&b39831) a novel drug with potential as an alternative to dacarbazine (1987) Cancer Res, 47, pp. 5846-5852
Newlands, E.S., Stevens, M.F., Wedge, S.R., Temozolomide: A review of its discovery chemical properties pre-clinical development and clinical trials (1997) Cancer Treat Rev, 23 (1), pp. 35-61
Simon, R., Optimal two-stage designs for phase II clinical trials (1989) Control Clin Trials, 10, pp. 1-10
Palmer, S.L., Goloubeva, O., Reddick, W.E., Patterns of intellectual development among survivors of pediatric medulloblastoma: A longitudinal analysis (2001) J Clin Oncol, 19, pp. 2302-2308
Dunkel, I.J., Gardner, S.L., Garvin Jr., J.H., High-dose carboplatin thiotepa and etoposide with autologous stem cell rescue for patients with previously irradiated recurrent medulloblastoma (2010) Neuro Oncol, 12 (3), pp. 297-303
Grill, J., Dufour, C., Kalifa, C., High-dose chemotherapy in children with newly-diagnosed medulloblastoma (2006) Lancet Oncol, 7, pp. 787-789
Finlay, J.L., Goldman, S., Wong, M.C., Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors (1996) J Clin Oncol, 14, pp. 2495-2503. , The Childrens Cancer Group
Baruchel, S., Diezi, M., Hargrave, D., Safety and pharmacokinetics of temozolomide using a dose-escalation metronomic schedule in recurrent paediatric brain tumours (2006) Eur J Cancer, 42, pp. 2335-2342
De Sio, L., Milano, G.M., Castellano, A., Temozolomide in resistant or relapsed pediatric solid tumors (2006) Pediatr Blood Cancer, 47, pp. 30-36
Hongeng, S., Visudtibhan, A., Dhanachai, M., Treatment of leptomeningeal relapse of medulloblastoma with temozolomide (2002) J Pediatr Hematol Oncol, 24, pp. 591-593
Poelen, J., Bernsen, H.J., Prick, M.J., Metastatic medulloblastoma in an adult
Treatment with temozolomide (2007) Acta Neurol Belg, 107 (2), pp. 51-54
Durando, X., Thivat, E., Gilliot, O., Temozolomide treatment of an adult with a relapsing medulloblastoma (2007) Cancer Invest, 25 (6), pp. 470-475
Riccardi, A., Mazzarella, G., Cefalo, G., Pharmacokinetics of temozolomide given three times a day in pediatric and adult patients (2003) Cancer Chemother Pharmacol, 52, pp. 459-464
Sardi, I., Cetica, V., Massimino, M., Promoter methylation and expression analysis of MGMT in advanced pediatric brain tumors (2009) Oncol Rep, 22 (4), pp. 773-779
Bobola, M.S., Tseng, S.H., Blank, A., Role of O6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin (1996) Clin Cancer Res, 2 (4), pp. 735-741
Ruggiero, A., Rizzo, D., Attinà, G., Phase i study of temozolomide combined with oral etoposide in children with recurrent or progressive medulloblastoma (2010) Eur J Cancer, 46 (16), pp. 2943-2949
Quinn, J.A., Jiang, S.X., Reardon, D.A., Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy (2009) J Neurooncol, 95 (3), pp. 393-400
Sasine, J.P., Savaraj, N., Feun, L.G., Topoisomerase i inhibitors in the treatment of primary CNS malignancies: An update on recent trends (2010) Anticancer Agents Med Chem, 10 (9), pp. 683-696
Lo, H.W., Cao, X., Zhu, H., Constitutively activated stat3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting stat3 sensitizes them to iressa and alkylators (2008) Clin Cancer Res, 14 (19), pp. 6042-6054
Goldhoff, P., Warrington, N.M., Limbrick Jr., D.D., Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression (2008) Clin Cancer Res, 14 (23), pp. 7717-7725
Taylor, R. E., Bailey, C. C., Robinson, K., Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The international society of paediatric oncology/united kingdom childrens cancer study group pnet-3 study (2003) J Clin Oncol, 21, pp. 1581-159
Evans, A. E., Jenkin, R. D., Sposto, R., The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU vincristine and prednisone (1990) J Neurosurg, 72, pp. 572-582
Bailey, C. C., Gnekow, A., Wellek, S., Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma (1995) Med Pediatr Oncol, 25, pp. 166-178. , International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II
Dunkel, I. J., Boyett, J. M., Yates, A., High-dose carboplatin thiotepa and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma (1998) J Clin Oncol, 16 (1), pp. 222-228. , Childrens Cancer Group
Walter, A. W., Mulhern, R. K., Gajjar, A., Survival and neurodevelopmental outcome of young children with medulloblastoma at St Jude Childrens Research Hospital (1999) J Clin Oncol, 17, pp. 3720-3728
Panetta, J. C., Kirstein, M. N., Gajjar, A., Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors (2003) Cancer Chemother Pharmacol, 52, pp. 435-441
Nicholson, H. S., Krailo, M., Ames, M. M., Phase i study of temozolomide in children and adolescents with recurrent solid tumors: A report from the Childrens Cancer Group (1998) J Clin Oncol, 16, pp. 3037-3043
Estlin, E. J., Lashford, L., Ablett, S., Phase i study of temozolomide in paediatric patients with advanced cancer (1998) Br J Cancer, 78 (5), pp. 652-661. , United Kingdom Childrens Cancer Study Group
Stevens, M. F., Hickman, J. A., Langdon, S. P., Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl- imidazo [5 i-d] -l235-tetrazin-4 (3h) -one (ccrg 81045
Newlands, E. S., Stevens, M. F., Wedge, S. R., Temozolomide: A review of its discovery chemical properties pre-clinical development and clinical trials (1997) Cancer Treat Rev, 23 (1), pp. 35-61
Palmer, S. L., Goloubeva, O., Reddick, W. E., Patterns of intellectual development among survivors of pediatric medulloblastoma: A longitudinal analysis (2001) J Clin Oncol, 19, pp. 2302-2308
Dunkel, I. J., Gardner, S. L., Garvin Jr., J. H., High-dose carboplatin thiotepa and etoposide with autologous stem cell rescue for patients with previously irradiated recurrent medulloblastoma (2010) Neuro Oncol, 12 (3), pp. 297-303
Finlay, J. L., Goldman, S., Wong, M. C., Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors (1996) J Clin Oncol, 14, pp. 2495-2503. , The Childrens Cancer Group
Bobola, M. S., Tseng, S. H., Blank, A., Role of O6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin (1996) Clin Cancer Res, 2 (4), pp. 735-741
Quinn, J. A., Jiang, S. X., Reardon, D. A., Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy (2009) J Neurooncol, 95 (3), pp. 393-400
Sasine, J. P., Savaraj, N., Feun, L. G., Topoisomerase i inhibitors in the treatment of primary CNS malignancies: An update on recent trends (2010) Anticancer Agents Med Chem, 10 (9), pp. 683-696
Lo, H. W., Cao, X., Zhu, H., Constitutively activated stat3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting stat3 sensitizes them to iressa and alkylators (2008) Clin Cancer Res, 14 (19), pp. 6042-6054
Neuro-Oncology (ISSN: 1522-8517), 2014 May; 16(5): 748-753.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 6.776, 5-year impact factor: 6.604
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-84899437120&partnerID=40&md5=b26db4c05154847234c3c954ac57948b
Keywords: Medulloblastoma, Phase Ii Trial, Temozolomide, Antiemetic Agent, Carboplatin, Cisplatin, Cyclophosphamide, Etoposide, Methotrexate, Nitrosourea Derivative, Vincristine, Adolescent, Adult, Anemia, Article, Bone Marrow Suppression, Cancer Chemotherapy, Cancer Growth, Chemotherapy Induced Nausea And Vomiting, Child, Childhood Cancer, Clinical Article, Craniospinal Irradiation, Drug Dose Reduction, Drug Efficacy, Drug Tolerability, Female, Histology, Human, Italy, Maintenance Chemotherapy, Multicenter Study, Neuroectoderm Tumor, Neutropenia, Overall Survival, Phase 2 Clinical Trial, Progression Free Survival, Thrombocytopenia, Treatment Response, Tumor Recurrence, Tumor Volume, Unspecified Side Effect,
Affiliations:
*** IBB - CNR ***
Pediatrics Unit, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy
Pediatric Oncology, A. Gemelli Hospital, Catholic University, Rome, Italy
Department of Radiodiagnostics, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy
Department of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy
Department of Neurosurgery, Ospedale G. Gaslini, Genova, Italy
Department of Pediatrics, University of Padua, Padua, Italy
Department of Bioimaging and Radiological Sciences, Catholic University, Rome, Italy
References:
Taylor, R.E., Bailey, C.C., Robinson, K., Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The international society of paediatric oncology/united kingdom childrens cancer study group pnet-3 study (2003) J Clin Oncol, 21, pp. 1581-159
Rutkowski, S., Bode, U., Deinlein, F., Treatment of early childhood medulloblastoma by postoperative chemotherapy alone (2005) N Engl J Med, 35, pp. 2978-2986
Evans, A.E., Jenkin, R.D., Sposto, R., The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU vincristine and prednisone (1990) J Neurosurg, 72, pp. 572-582
Bailey, C.C., Gnekow, A., Wellek, S., Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma (1995) Med Pediatr Oncol, 25, pp. 166-178. , International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II
Gatta, G., Capocaccia, R., Coleman, M.P., Childhood cancer survival in Europe and the United States (2002) Cancer, 95 (8), pp. 1767-1772
Dunkel, I.J., Boyett, J.M., Yates, A., High-dose carboplatin thiotepa and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma (1998) J Clin Oncol, 16 (1), pp. 222-228. , Childrens Cancer Group
Massimino, M., Casanova, M., Polastri, D., Relapse in medulloblastoma: What can be done after abandoning high-dose chemotherapy? A mono-institutional experience (2013) Childs Nerv Syst, 29, pp. 1107-1112
Bouffet, E., Doz, F., Demaille, M.C., Improving survival in recurrent medulloblastoma: Earlier detection better treatment or still an impasse? (1998) Br J Cancer, 77, pp. 1321-1326
Gajjar, A., Pizer, B., Role of high-dose chemotherapy for recurrent medulloblastoma and other CNS primitive neuroectodermal tumors (2010) Pediatr Blood Cancer, 54 (4), pp. 649-651
Walter, A.W., Mulhern, R.K., Gajjar, A., Survival and neurodevelopmental outcome of young children with medulloblastoma at St Jude Childrens Research Hospital (1999) J Clin Oncol, 17, pp. 3720-3728
Ostermann, S., Csajka, C., Buclin, T., Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients (2004) Clin Cancer Res, 10, pp. 3728-3736
Panetta, J.C., Kirstein, M.N., Gajjar, A., Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors (2003) Cancer Chemother Pharmacol, 52, pp. 435-441
Patel, M., McCully, C., Godwin, K., Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates (2003) J Neurooncol, 61, pp. 203-207
Ruggiero, A., Cefalo, G., Garré, M.L., Phase II trial of temozolomide in children with recurrent high-grade glioma (2006) J Neurooncol, 77, pp. 89-94
Nicholson, H.S., Krailo, M., Ames, M.M., Phase i study of temozolomide in children and adolescents with recurrent solid tumors: A report from the Childrens Cancer Group (1998) J Clin Oncol, 16, pp. 3037-3043
Estlin, E.J., Lashford, L., Ablett, S., Phase i study of temozolomide in paediatric patients with advanced cancer (1998) Br J Cancer, 78 (5), pp. 652-661. , United Kingdom Childrens Cancer Study Group
Stevens, M.F., Hickman, J.A., Langdon, S.P., Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl- imidazo[5 i-d]-l235-tetrazin-4(3h)-one (ccrg 81045
m&b39831) a novel drug with potential as an alternative to dacarbazine (1987) Cancer Res, 47, pp. 5846-5852
Newlands, E.S., Stevens, M.F., Wedge, S.R., Temozolomide: A review of its discovery chemical properties pre-clinical development and clinical trials (1997) Cancer Treat Rev, 23 (1), pp. 35-61
Simon, R., Optimal two-stage designs for phase II clinical trials (1989) Control Clin Trials, 10, pp. 1-10
Palmer, S.L., Goloubeva, O., Reddick, W.E., Patterns of intellectual development among survivors of pediatric medulloblastoma: A longitudinal analysis (2001) J Clin Oncol, 19, pp. 2302-2308
Dunkel, I.J., Gardner, S.L., Garvin Jr., J.H., High-dose carboplatin thiotepa and etoposide with autologous stem cell rescue for patients with previously irradiated recurrent medulloblastoma (2010) Neuro Oncol, 12 (3), pp. 297-303
Grill, J., Dufour, C., Kalifa, C., High-dose chemotherapy in children with newly-diagnosed medulloblastoma (2006) Lancet Oncol, 7, pp. 787-789
Finlay, J.L., Goldman, S., Wong, M.C., Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors (1996) J Clin Oncol, 14, pp. 2495-2503. , The Childrens Cancer Group
Baruchel, S., Diezi, M., Hargrave, D., Safety and pharmacokinetics of temozolomide using a dose-escalation metronomic schedule in recurrent paediatric brain tumours (2006) Eur J Cancer, 42, pp. 2335-2342
De Sio, L., Milano, G.M., Castellano, A., Temozolomide in resistant or relapsed pediatric solid tumors (2006) Pediatr Blood Cancer, 47, pp. 30-36
Hongeng, S., Visudtibhan, A., Dhanachai, M., Treatment of leptomeningeal relapse of medulloblastoma with temozolomide (2002) J Pediatr Hematol Oncol, 24, pp. 591-593
Poelen, J., Bernsen, H.J., Prick, M.J., Metastatic medulloblastoma in an adult
Treatment with temozolomide (2007) Acta Neurol Belg, 107 (2), pp. 51-54
Durando, X., Thivat, E., Gilliot, O., Temozolomide treatment of an adult with a relapsing medulloblastoma (2007) Cancer Invest, 25 (6), pp. 470-475
Riccardi, A., Mazzarella, G., Cefalo, G., Pharmacokinetics of temozolomide given three times a day in pediatric and adult patients (2003) Cancer Chemother Pharmacol, 52, pp. 459-464
Sardi, I., Cetica, V., Massimino, M., Promoter methylation and expression analysis of MGMT in advanced pediatric brain tumors (2009) Oncol Rep, 22 (4), pp. 773-779
Bobola, M.S., Tseng, S.H., Blank, A., Role of O6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin (1996) Clin Cancer Res, 2 (4), pp. 735-741
Ruggiero, A., Rizzo, D., Attinà, G., Phase i study of temozolomide combined with oral etoposide in children with recurrent or progressive medulloblastoma (2010) Eur J Cancer, 46 (16), pp. 2943-2949
Quinn, J.A., Jiang, S.X., Reardon, D.A., Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy (2009) J Neurooncol, 95 (3), pp. 393-400
Sasine, J.P., Savaraj, N., Feun, L.G., Topoisomerase i inhibitors in the treatment of primary CNS malignancies: An update on recent trends (2010) Anticancer Agents Med Chem, 10 (9), pp. 683-696
Lo, H.W., Cao, X., Zhu, H., Constitutively activated stat3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting stat3 sensitizes them to iressa and alkylators (2008) Clin Cancer Res, 14 (19), pp. 6042-6054
Goldhoff, P., Warrington, N.M., Limbrick Jr., D.D., Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression (2008) Clin Cancer Res, 14 (23), pp. 7717-7725
Taylor, R. E., Bailey, C. C., Robinson, K., Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The international society of paediatric oncology/united kingdom childrens cancer study group pnet-3 study (2003) J Clin Oncol, 21, pp. 1581-159
Evans, A. E., Jenkin, R. D., Sposto, R., The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU vincristine and prednisone (1990) J Neurosurg, 72, pp. 572-582
Bailey, C. C., Gnekow, A., Wellek, S., Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma (1995) Med Pediatr Oncol, 25, pp. 166-178. , International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II
Dunkel, I. J., Boyett, J. M., Yates, A., High-dose carboplatin thiotepa and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma (1998) J Clin Oncol, 16 (1), pp. 222-228. , Childrens Cancer Group
Walter, A. W., Mulhern, R. K., Gajjar, A., Survival and neurodevelopmental outcome of young children with medulloblastoma at St Jude Childrens Research Hospital (1999) J Clin Oncol, 17, pp. 3720-3728
Panetta, J. C., Kirstein, M. N., Gajjar, A., Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors (2003) Cancer Chemother Pharmacol, 52, pp. 435-441
Nicholson, H. S., Krailo, M., Ames, M. M., Phase i study of temozolomide in children and adolescents with recurrent solid tumors: A report from the Childrens Cancer Group (1998) J Clin Oncol, 16, pp. 3037-3043
Estlin, E. J., Lashford, L., Ablett, S., Phase i study of temozolomide in paediatric patients with advanced cancer (1998) Br J Cancer, 78 (5), pp. 652-661. , United Kingdom Childrens Cancer Study Group
Stevens, M. F., Hickman, J. A., Langdon, S. P., Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl- imidazo [5 i-d] -l235-tetrazin-4 (3h) -one (ccrg 81045
Newlands, E. S., Stevens, M. F., Wedge, S. R., Temozolomide: A review of its discovery chemical properties pre-clinical development and clinical trials (1997) Cancer Treat Rev, 23 (1), pp. 35-61
Palmer, S. L., Goloubeva, O., Reddick, W. E., Patterns of intellectual development among survivors of pediatric medulloblastoma: A longitudinal analysis (2001) J Clin Oncol, 19, pp. 2302-2308
Dunkel, I. J., Gardner, S. L., Garvin Jr., J. H., High-dose carboplatin thiotepa and etoposide with autologous stem cell rescue for patients with previously irradiated recurrent medulloblastoma (2010) Neuro Oncol, 12 (3), pp. 297-303
Finlay, J. L., Goldman, S., Wong, M. C., Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors (1996) J Clin Oncol, 14, pp. 2495-2503. , The Childrens Cancer Group
Bobola, M. S., Tseng, S. H., Blank, A., Role of O6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin (1996) Clin Cancer Res, 2 (4), pp. 735-741
Quinn, J. A., Jiang, S. X., Reardon, D. A., Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy (2009) J Neurooncol, 95 (3), pp. 393-400
Sasine, J. P., Savaraj, N., Feun, L. G., Topoisomerase i inhibitors in the treatment of primary CNS malignancies: An update on recent trends (2010) Anticancer Agents Med Chem, 10 (9), pp. 683-696
Lo, H. W., Cao, X., Zhu, H., Constitutively activated stat3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting stat3 sensitizes them to iressa and alkylators (2008) Clin Cancer Res, 14 (19), pp. 6042-6054
Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: An Italian multi-institutional phase II trial
BackgroundThe aim of this study was to assess the objective response rate (ORR) of children and young adults with recurrent medulloblastoma/primitive neuroectodermal tumor (MB/PNET) treated with temozolomide (TMZ). The secondary purpose was to analyze the toxicity profile of TMZ when administered orally for 5 days in 3 divided daily doses every 28 days.MethodsForty-two patients with recurrent MB/PNET, aged 21 years and younger, were recruited. Patients were treated with oral TMZ. Starting doses ranged from 120 to 200 mg/m 2/day based on previous treatments. A craniospinal MRI was performed prior to the first cycle of TMZ and following every 2 cycles of treatment.ResultsMedian age was 10 years (range, 2-21 years). Forty of 42 patients were assessed for response and toxicity. The objective response rate was 42.5%: 6 patients achieved a complete response, 11 had a partial response, and 10 had stable disease. Progression-free survival rates for all patients at 6 and 12 months were 30% and 7.5%, respectively. Their median overall survival rates at 6 and 12 months were 42.5% and 17.5%, respectively. No major extrahematological effects or life-threatening events were reported. The most common grade 3/4 toxicity included thrombocytopenia (17.5%), neutropenia (7.5%), and anemia (2.5%).ConclusionsTMZ proved to be an effective agent in children and young adults with MB/PNET, heavily pre-treated, with a tolerable toxicity profile. © 2014 © The Author(s) 2014. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
BackgroundThe aim of this study was to assess the objective response rate (ORR) of children and young adults with recurrent medulloblastoma/primitive neuroectodermal tumor (MB/PNET) treated with temozolomide (TMZ). The secondary purpose was to analyze the toxicity profile of TMZ when administered orally for 5 days in 3 divided daily doses every 28 days.MethodsForty-two patients with recurrent MB/PNET, aged 21 years and younger, were recruited. Patients were treated with oral TMZ. Starting doses ranged from 120 to 200 mg/m 2/day based on previous treatments. A craniospinal MRI was performed prior to the first cycle of TMZ and following every 2 cycles of treatment.ResultsMedian age was 10 years (range, 2-21 years). Forty of 42 patients were assessed for response and toxicity. The objective response rate was 42.5%: 6 patients achieved a complete response, 11 had a partial response, and 10 had stable disease. Progression-free survival rates for all patients at 6 and 12 months were 30% and 7.5%, respectively. Their median overall survival rates at 6 and 12 months were 42.5% and 17.5%, respectively. No major extrahematological effects or life-threatening events were reported. The most common grade 3/4 toxicity included thrombocytopenia (17.5%), neutropenia (7.5%), and anemia (2.5%).ConclusionsTMZ proved to be an effective agent in children and young adults with MB/PNET, heavily pre-treated, with a tolerable toxicity profile. © 2014 © The Author(s) 2014. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: An Italian multi-institutional phase II trial
| ▼ Characterization of the KCTD protein family: key factors in several biological processes |
Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: An Italian multi-institutional phase II trial
Other filter: ([btitle,keywords] "Medulloblastoma" OR ...
Ferrucci V, De Antonellis P, Pennino FP, Asadzadeh F, Virgilio A, Montanaro D, Galeone A, Boffa I, Pisano I, Scognamiglio I, Navas L, Diana D, Pedone E, Gargiulo S, Gramanzini M, Brunetti A, Danielson L, Carotenuto M, Liguori L, Verrico A, Quaglietta L, Errico ME, Del Monaco V, D'Argenio V, Tirone F, Mastronuzzi A, Donofrio V, Giangaspero F, Picard D, Remke M, Garzia L, Daniels C, Delattre O, Swartling FJ, Weiss WA, Salvatore F, Fattorusso R, Chesler L, Taylor MD, Cinalli G, Zollo M
* Metastatic group 3 medulloblastoma is driven by PRUNE1 targeting NME1-TGF-beta-OTX2-SNAIL via PTEN inhibition (1252 views)
Brain (ISSN: 1460-2156electronic, 0006-8950linking), 2018 May 1; 141(5): 1300-1319.
Impact Factor: 9.915
View Export to BibTeX Export to EndNote
Picone D, Donnarumma F, Ferraro G, Gotte G, Fagagnini A, Butera G, Donadelli M, Merlino A
* A comparison study on RNase A oligomerization induced by cisplatin, carboplatin and oxaliplatin (343 views)
J Chem Res (ISSN: 0162-0134, 1873-3344, 0162-0134print), 2017 Aug; 173: 105-112.
Impact Factor: 3.063
View Export to BibTeX Export to EndNote
Pontillo N, Ferraro G, Helliwell JR, Amoresano A, Merlino A
* X-ray Structure of the Carboplatin-Loaded Apo-Ferritin Nanocage (236 views)
Acs Med Chem Lett (ISSN: 1948-5875, 1948-5875linking), 2017 Feb 28; 8(4): 433-437.
Impact Factor: 3.794
View Export to BibTeX Export to EndNote
Crisci V, Mainenti PP, Corvino F, Lauria R, Maurea S
* Bone involvement by adenocarcinoma of the uterine cervix: a rare entity (285 views)
Pol J Radiol (ISSN: 0137-7183, 1733-134x, 1733-134xlinking), 2015 Feb 14; 80(1): 81-84.
Impact Factor: 0.567
View Export to BibTeX Export to EndNote
Messori L, Marzo T, Merlino A
* Interactions of carboplatin and oxaliplatin with proteins: Insights from X-ray structures and mass spectrometry studies of their ribonuclease A adducts (312 views)
J Chem Res (ISSN: 0162-0134, 1873-3344, 0162-0134print), 2015; N/D: N/D-N/D.
Impact Factor: 3.205
View Export to BibTeX Export to EndNote
Insabato L, Natella V, Somma A, Persico M, Camera L, Losito NS, Masone S
* Primary Peritoneal Clear Cell Carcinoma Versus Ovarian Carcinoma Versus Malignant Transformation of Endometriosis: A Vexing Issue (303 views)
Int J Surg Pathol (ISSN: 1066-8969), 2015; 23(3): 211-216.
Impact Factor: 0.782
View Export to BibTeX Export to EndNote
Pedicini P, Fiorentino A, Simeon V, Tini P, Chiumento C, Pirtoli L, Salvatore M, Storto G
* Clinical radiobiology of glioblastoma multiforme: estimation of tumor control probability from various radiotherapy fractionation schemes (387 views)
Strahlenther Onkol (ISSN: 0179-7158, 0179-7158linking), 2014 Oct; 190(10): 925-932.
Impact Factor: 2.914
View Export to BibTeX Export to EndNote
Orditura M, Galizia G, Morgillo F, Martinelli E, Lieto E, Vitiello F, Di Martino N, Pacelli R, Renda A, Ciardiello F, De Vita F
* Complete Response To Preoperative Chemoradiation And Survival In Esophageal Cancer: A Pooled Analysis Of Three Single-Institution Phase Ii Trials (394 views)
Diseases Of The Esophagus, 2012 Feb; 142(5): 130-136.
Impact Factor: 2.057
View Export to BibTeX Export to EndNote
Correale S, Pirone L, Di Marcotullio L, De Smaele E, Greco A, Mazzà D, Moretti M, Alterio V, Vitagliano L, Di Gaetano S, Gulino A, Pedone E
* Molecular organization of the cullin E3 ligase adaptor KCTD11 (568 views)
Biochimie (ISSN: 0300-9084, 1638-6183, 1638-6183electronic), 2011 Apr; 93(4): 715-724.
Impact Factor: 3.022
View Export to BibTeX Export to EndNote
Canettieri G, Di Marcotullio L, Greco A, Coni S, Antonucci L, Infante P, Pietrosanti L, De Smaele E, Ferretti E, Miele E, Pelloni M, De Simone G, Pedone E, Gallinari P, Giorgi A, Steinkuhler C, Vitagliano L, Pedone C, Schinin ME, Screpanti I, Gulino A
* Histone deacetylase and Cullin3-REN(KCTD11) ubiquitin ligase interplay regulates Hedgehog signalling through Gli acetylation (688 views)
Nature Cell Biol Nature Cell Biology (ISSN: 1476-4679, 1465-7392), 2010 Feb; 12(2): 132-142.
Impact Factor: 19.407
View Export to BibTeX Export to EndNote
Peca C, Pacelli R, Elefante A, Del Basso De Caro ML, Vergara P, Mariniello G, Giamundo A, Maiuri F
* Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: Tumour progression or radionecrosis? (373 views)
Clin Neurol Neurosurg (ISSN: 0303-8467), 2009 May; 111(4): 331-334.
Impact Factor: 1.303
View Export to BibTeX Export to EndNote
Garzia L, Andolfo I, Cusanelli E, Marino N, Petrosino G, De Martino D, Esposito V, Galeone A, Navas L, Esposito S, Gargiulo S, Fattet S, Donofrio V, Cinalli G, Brunetti A, Del Vecchio L, Northcott PA, Delattre O, Taylor MD, Iolascon A, Zollo M
* MicroRNA-199b-5p Impairs Cancer Stem Cells through Negative Regulation of HES1 in Medulloblastoma (442 views)
Plosone (ISSN: 1932-6203, 1932-6203electronic, 1932-6203linking), 2009 Mar 24; 4(3): e4998-e4998.
Impact Factor: 4.351
View Export to BibTeX Export to EndNote
Miralbell R, Lomax A, Cella L, Schneider U
* Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors (262 views)
Int J Radiat Oncol (ISSN: 0360-3016, 1879-355x, 1879-355xelectronic), 2002 Nov 1; 54(3): 824-829.
Impact Factor: 3.756
View Export to BibTeX Export to EndNote
Gridelli C, Manzione L, Perrone F, Veltri E, Cioffi R, Caprio MG, Frontini L, Rossi A, Barletta E, Barzelloni ML, Bilancia D, Gallo C
* Carboplatin plus paclitaxel in extensive small cell lung cancer: a multicentre phase 2 study (255 views) (PDF 220 views)
Br J Cancer (ISSN: 0007-0920print, 0007-0920linking), 2001 Jan 5; 84(1): 38-41.
Impact Factor: 3.942
View Export to BibTeX Export to EndNote
* Metastatic group 3 medulloblastoma is driven by PRUNE1 targeting NME1-TGF-beta-OTX2-SNAIL via PTEN inhibition (1252 views)
Brain (ISSN: 1460-2156electronic, 0006-8950linking), 2018 May 1; 141(5): 1300-1319.
Impact Factor: 9.915
View Export to BibTeX Export to EndNote
Picone D, Donnarumma F, Ferraro G, Gotte G, Fagagnini A, Butera G, Donadelli M, Merlino A
* A comparison study on RNase A oligomerization induced by cisplatin, carboplatin and oxaliplatin (343 views)
J Chem Res (ISSN: 0162-0134, 1873-3344, 0162-0134print), 2017 Aug; 173: 105-112.
Impact Factor: 3.063
View Export to BibTeX Export to EndNote
Pontillo N, Ferraro G, Helliwell JR, Amoresano A, Merlino A
* X-ray Structure of the Carboplatin-Loaded Apo-Ferritin Nanocage (236 views)
Acs Med Chem Lett (ISSN: 1948-5875, 1948-5875linking), 2017 Feb 28; 8(4): 433-437.
Impact Factor: 3.794
View Export to BibTeX Export to EndNote
Crisci V, Mainenti PP, Corvino F, Lauria R, Maurea S
* Bone involvement by adenocarcinoma of the uterine cervix: a rare entity (285 views)
Pol J Radiol (ISSN: 0137-7183, 1733-134x, 1733-134xlinking), 2015 Feb 14; 80(1): 81-84.
Impact Factor: 0.567
View Export to BibTeX Export to EndNote
Messori L, Marzo T, Merlino A
* Interactions of carboplatin and oxaliplatin with proteins: Insights from X-ray structures and mass spectrometry studies of their ribonuclease A adducts (312 views)
J Chem Res (ISSN: 0162-0134, 1873-3344, 0162-0134print), 2015; N/D: N/D-N/D.
Impact Factor: 3.205
View Export to BibTeX Export to EndNote
Insabato L, Natella V, Somma A, Persico M, Camera L, Losito NS, Masone S
* Primary Peritoneal Clear Cell Carcinoma Versus Ovarian Carcinoma Versus Malignant Transformation of Endometriosis: A Vexing Issue (303 views)
Int J Surg Pathol (ISSN: 1066-8969), 2015; 23(3): 211-216.
Impact Factor: 0.782
View Export to BibTeX Export to EndNote
Pedicini P, Fiorentino A, Simeon V, Tini P, Chiumento C, Pirtoli L, Salvatore M, Storto G
* Clinical radiobiology of glioblastoma multiforme: estimation of tumor control probability from various radiotherapy fractionation schemes (387 views)
Strahlenther Onkol (ISSN: 0179-7158, 0179-7158linking), 2014 Oct; 190(10): 925-932.
Impact Factor: 2.914
View Export to BibTeX Export to EndNote
Orditura M, Galizia G, Morgillo F, Martinelli E, Lieto E, Vitiello F, Di Martino N, Pacelli R, Renda A, Ciardiello F, De Vita F
* Complete Response To Preoperative Chemoradiation And Survival In Esophageal Cancer: A Pooled Analysis Of Three Single-Institution Phase Ii Trials (394 views)
Diseases Of The Esophagus, 2012 Feb; 142(5): 130-136.
Impact Factor: 2.057
View Export to BibTeX Export to EndNote
Correale S, Pirone L, Di Marcotullio L, De Smaele E, Greco A, Mazzà D, Moretti M, Alterio V, Vitagliano L, Di Gaetano S, Gulino A, Pedone E
* Molecular organization of the cullin E3 ligase adaptor KCTD11 (568 views)
Biochimie (ISSN: 0300-9084, 1638-6183, 1638-6183electronic), 2011 Apr; 93(4): 715-724.
Impact Factor: 3.022
View Export to BibTeX Export to EndNote
Canettieri G, Di Marcotullio L, Greco A, Coni S, Antonucci L, Infante P, Pietrosanti L, De Smaele E, Ferretti E, Miele E, Pelloni M, De Simone G, Pedone E, Gallinari P, Giorgi A, Steinkuhler C, Vitagliano L, Pedone C, Schinin ME, Screpanti I, Gulino A
* Histone deacetylase and Cullin3-REN(KCTD11) ubiquitin ligase interplay regulates Hedgehog signalling through Gli acetylation (688 views)
Nature Cell Biol Nature Cell Biology (ISSN: 1476-4679, 1465-7392), 2010 Feb; 12(2): 132-142.
Impact Factor: 19.407
View Export to BibTeX Export to EndNote
Peca C, Pacelli R, Elefante A, Del Basso De Caro ML, Vergara P, Mariniello G, Giamundo A, Maiuri F
* Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: Tumour progression or radionecrosis? (373 views)
Clin Neurol Neurosurg (ISSN: 0303-8467), 2009 May; 111(4): 331-334.
Impact Factor: 1.303
View Export to BibTeX Export to EndNote
Garzia L, Andolfo I, Cusanelli E, Marino N, Petrosino G, De Martino D, Esposito V, Galeone A, Navas L, Esposito S, Gargiulo S, Fattet S, Donofrio V, Cinalli G, Brunetti A, Del Vecchio L, Northcott PA, Delattre O, Taylor MD, Iolascon A, Zollo M
* MicroRNA-199b-5p Impairs Cancer Stem Cells through Negative Regulation of HES1 in Medulloblastoma (442 views)
Plosone (ISSN: 1932-6203, 1932-6203electronic, 1932-6203linking), 2009 Mar 24; 4(3): e4998-e4998.
Impact Factor: 4.351
View Export to BibTeX Export to EndNote
Miralbell R, Lomax A, Cella L, Schneider U
* Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors (262 views)
Int J Radiat Oncol (ISSN: 0360-3016, 1879-355x, 1879-355xelectronic), 2002 Nov 1; 54(3): 824-829.
Impact Factor: 3.756
View Export to BibTeX Export to EndNote
Gridelli C, Manzione L, Perrone F, Veltri E, Cioffi R, Caprio MG, Frontini L, Rossi A, Barletta E, Barzelloni ML, Bilancia D, Gallo C
* Carboplatin plus paclitaxel in extensive small cell lung cancer: a multicentre phase 2 study (255 views) (PDF 220 views)
Br J Cancer (ISSN: 0007-0920print, 0007-0920linking), 2001 Jan 5; 84(1): 38-41.
Impact Factor: 3.942
View Export to BibTeX Export to EndNote
14 Records (13 excluding Abstracts).
Total impact factor: 62.078 (57.727 excluding Abstracts).
Total 5 year impact factor: 65.291 (60.908 excluding Abstracts).
Total impact factor: 62.078 (57.727 excluding Abstracts).
Total 5 year impact factor: 65.291 (60.908 excluding Abstracts).
369 views. Last view on Tuesday 11 April 2023, 11:52:26
ibb.cnr.it
